Clinical trials
Phase 2 Lymphoma, B-Cell, Marginal Zone trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 13 |
| Completed | 6 |
| Active, not recruiting | 5 |
| Not yet recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| BeiGene | 2 |
| Ruijin Hospital | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Sun Yat-sen University | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Chinese PLA General Hospital | 1 |
| Eli Lilly and Company | 1 |
| Fei Li | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, B-Cell, Marginal Zone | 28 |
| Lymphoma, Follicular | 6 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Lymphoma, B-Cell | 2 |
| Lymphoma, Mantle-Cell | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Leukemia, Lymphoid | 1 |
| Lymphoma | 1 |
| Lymphoma, Non-Hodgkin | 1 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.